Aligos Therapeutics, Inc.
No SEC Form 4 filings for $ALGS in the last 30 days.
See all $ALGS insider activity →Novo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.
Aligos Therapeutics, Inc. (ALGS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into the First Amendment to Lease (the “First Amendment”) with Britannia Biotech Gateway Limited Partnership (the “Landlord”), to amend the Lease, dated
Aligos Therapeutics (ALGS) stock rose 7.6% in pre-market trading to $6.55, despite a broader market decline. The rally follows recent operational milestones, better-than-expected Q2 2026 earnings, and a completed Phase 2 study enrollment for its hepatitis B treatment. The company's balance sheet was strengthened by a licensing deal. The stock remains below its 52-week high of $13.69.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ALGS (Aligos Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent ALGS coverage spans mergers & acquisitions, corporate actions and market movers.
Sharp sell‑off suggests adverse news or missed expectations.
The lease extension secures the company's headquarters location but adds incremental rent costs and a termination fee, modestly affecting cash flow.
The pre‑open surge suggests short‑term buying pressure but lacks a fresh catalyst.
Near-term focus is funding runway and milestone timing, while the main catalyst is late Q3 2027 topline for B-SUPREME.
The upfront cash and milestone structure de-risks near-term funding while signaling progress toward China clinical development for ALG-170675.
AlphAI scores every news story that mentions ALGS with an AI model for sentiment and relevance, and aggregates insider trades from Aligos Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Novo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.
2 min readAligos Therapeutics, Inc. (ALGS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into the First Amendment to Lease (the “First Amendment”) with Britannia Biotech Gateway Limited Partnership (the “Landlord”), to amend the Lease, dated
1 min readAligos Therapeutics (ALGS) stock rose 7.6% in pre-market trading to $6.55, despite a broader market decline. The rally follows recent operational milestones, better-than-expected Q2 2026 earnings, and a completed Phase 2 study enrollment for its hepatitis B treatment. The company's balance sheet was strengthened by a licensing deal. The stock remains below its 52-week high of $13.69.
1 min readAligos Therapeutics, Inc. (ALGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improvi
6 min readAligos Therapeutics (ALGS) said it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China license for Pevifoscorvir sodium for chronic HBV. The therapy received China’s NMPA Breakthrough Therapy Designation. Aligos may earn up to $420M in milestones plus tiered royalties; Amoytop plans to start China development of ALG-170675 later this year.
3 min readAligos Therapeutics (ALGS) shares rose about 19.9% in after-hours after the company said it received a $25 million upfront cash payment from Xiamen Amoytop Biotech under an exclusive Greater China licensing deal for pevifoscorvir sodium for chronic HBV. Aligos may receive up to $420 million in milestones plus royalties; the deal extends its cash runway into Q4 2026.
3 min readAligos Therapeutics (Nasdaq: ALGS) said it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China license for pevifoscorvir sodium for chronic hepatitis B. The drug also received China NMPA CDE Breakthrough Therapy Designation, which may enable priority NDA review. Aligos could earn up to $420M in milestones plus royalties; it keeps rights in the US, Europe, Japan, and other markets.
3 min readAligos Therapeutics (NASDAQ:ALGS) shares rose about 21% after hours after it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China licensing deal for pevifoscorvir sodium for chronic hepatitis B. Aligos can earn up to $420M milestones plus royalties; the drug also received China Breakthrough Therapy Designation.
3 min readAligos Therapeutics, Inc. (ALGS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001799448 0001799448 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,
4 min readLake Street Capital began coverage of Aligos Therapeutics (NASDAQ:ALGS), assigning a “buy” rating and a $45.00 price target, according to MarketBeat Ratings. Other analysts cited mixed views, with Cantor “overweight” at $20 and Westpark “buy” at $48; MarketBeat shows a $38.50 consensus target. ALGS reported May 7 EPS of -$2.21 vs -$2.29 expected and revenue of $2.83M vs $0.25M.
3 min read
